Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,903 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Cancer Clear all
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

NCT02755272
View directory record Official record
Conditions
Carcinoma Breast Stage IV
Interventions
Pembrolizumab, Carboplatin, Gemcitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
6
States / cities
Indianapolis, Indiana • St Louis, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

NCT01073267
View directory record Official record
Conditions
Lymphoma
Interventions
TSEBT
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 21, 2026, 7:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NCT03127098
View directory record Official record
Conditions
Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer
Interventions
ETBX-011, ALT-803
Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 7:36 PM EDT
Active, not recruiting Not applicable Interventional

Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors

NCT06260332
View directory record Official record
Conditions
Breast Cancer
Interventions
Supportive Care (Fitbit)
Behavioral
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

NCT00165204
View directory record Official record
Conditions
Menopause, Postmenopausal Bone Loss, Breast Cancer
Interventions
Tibolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

NCT00093145
View directory record Official record
Conditions
Breast Cancer
Interventions
Albumin-bound paclitaxel, Carboplatin, Herceptin®
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
14
States / cities
Long Beach, California • Stamford, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

NCT00788775
View directory record Official record
Conditions
Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
Interventions
Nilotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Santa Monica, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 21, 2026, 7:36 PM EDT
Terminated No phase listed Observational

Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration

NCT02339987
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 21, 2026, 7:36 PM EDT
Terminated Phase 2 Interventional Results available

PROactive Evaluation of Function to Avoid CardioToxicity

NCT03862131
View directory record Official record
Conditions
Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
Interventions
MyoStrain®
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 1 Interventional

Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

NCT01505153
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumors
Interventions
pbi-shRNA STMN1 LP
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 1 Interventional

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

NCT01155453
View directory record Official record
Conditions
Advanced and Selected Solid Tumors
Interventions
BKM120, GSK1120212
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 21, 2026, 7:36 PM EDT
Completed No phase listed Observational

Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer

NCT00666731
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
medical chart review, questionnaire administration, study of socioeconomic and demographic variables, Excess human biological tissue, quality-of-life assessment
Other · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
4,945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
65
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Results available

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

NCT00876395
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Placebo, Trastuzumab, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
25
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

NCT02296801
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Breast Tumors
Interventions
Letrozole, palbociclib
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Long Beach, California • Miami, Florida • Decatur, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional

Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

NCT00002167
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tin ethyl etiopurpurin
Drug
Lead sponsor
Clinical Solutions
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

NCT00048321
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ISIS 104838
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 1 Interventional

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

NCT00349206
View directory record Official record
Conditions
Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
sorafenib tosylate, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 1 Interventional

Study of Continuous OSI-906 Dosing

NCT00514007
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 21, 2026, 7:36 PM EDT
Active, not recruiting Not applicable Interventional Results available

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

NCT03070236
View directory record Official record
Conditions
Breast Cancer
Interventions
Survey
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
6
States / cities
Boston, Massachusetts • Newton, Massachusetts • Weymouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 21, 2026, 7:36 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Rehabilitation of Cognitive Changes in Breast Cancer Survivors

NCT01182506
View directory record Official record
Conditions
Breast Cancer
Interventions
Cogmed Working Memory Training Program
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 69 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 7:36 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

NCT05226663
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

NCT01321437
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
Interventions
therapeutic conventional surgery, laboratory biomarker analysis, Axitinib, pharmacological study
Procedure · Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 1 Interventional

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

NCT00413075
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 21, 2026, 7:36 PM EDT
Completed Phase 1 Interventional

Optical Clearing of the Skin in Conjunction With Laser Treatments

NCT00580736
View directory record Official record
Conditions
Port Wine Stain, Nevus of Ota, Tattoos, Scars, Acne, Hypertrichosis, Sebaceous Gland Diseases
Interventions
Optical Clearing
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 21, 2026, 7:36 PM EDT